IL1B and hydrops fetalis: Various clinical trials studying colchicine or IL‐1 inhibition in stable or acutely decompensated HF with reduced ejection fraction (reviewed in Olsen et al. 136)have also failed to convincingly demonstrate a strong protective potential.